NYSE · ITGR
Integer Holdings Corporation
$126.52-$0.03 (-0.02%)
Integer Holdings Corporation’s quoted price sits in the upper half of its reported 52-week range, 0.24% below the high.
Loading market information…
NYSE · INSP · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Inspire Medical Systems, Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.59% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Inspire Medical Systems, Inc.’s next earnings report is currently expected on Nov 2, 2026, with estimated earnings per share of $0.09. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Inspire Medical Systems, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Inspire Medical Systems, Inc. operates as a medical technology enterprise, concentrating on the development and commercialization of advanced, minimally intrusive therapies for patients diagnosed with obstructive sleep apnea (OSA) across both domestic U.S. and international markets. A cornerstone of its product portfolio is the Inspire system, an innovative neurostimulation solution that offers a safe and proven effective treatment for individuals experiencing moderate to severe forms of OSA. Additionally, the company is pioneering a novel, closed-loop technology designed to continuously track a patient's breathing patterns and administer mild stimulation to the hypoglossal nerve, thereby maintaining an open airway. Founded in 2007, Inspire Medical Systems maintains its corporate headquarters in Golden Valley, Minnesota.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:13 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 5, 2025 | $0.10+143.48% vs estimate | $201.32M-11.59% vs estimate |
|---|
| Q4 2024 | Feb 10, 2025 | $1.15+55.41% vs estimate | $239.72M-0.02% vs estimate |
|---|
| Q3 2024 | Nov 4, 2024 | $0.60+650.0% vs estimate | $203.19M+2.83% vs estimate |
|---|
THE ANALYST VIEW
28 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 11 contributors · Median target $62.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$126.52-$0.03 (-0.02%)
Integer Holdings Corporation’s quoted price sits in the upper half of its reported 52-week range, 0.24% below the high.
$10.27+$0.29 (+2.91%)
Brookdale Senior Living Inc.’s quoted price sits in the lower half of its reported 52-week range, 39.91% below the high.
$18.61+$0.22 (+1.2%)
Arcus Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 41.37% below the high.
$124.34+$2.16 (+1.77%)
Addus HomeCare Corporation’s quoted price sits in the upper half of its reported 52-week range, 0.92% below the high.
$14.84$0.00 (0.0%)
89bio, Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.46% below the high.
$85.27+$2.40 (+2.9%)
LeMaitre Vascular, Inc.’s quoted price sits in the lower half of its reported 52-week range, 27.74% below the high.
$12.30+$0.37 (+3.1%)
Ardent Health Inc.’s quoted price sits in the upper half of its reported 52-week range, 18.49% below the high.
$20.30+$0.10 (+0.5%)
PROCEPT BioRobotics Corporation’s quoted price sits in the lower half of its reported 52-week range, 46.73% below the high.
